Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Definitive childlessness in women with multiple sclerosis: a multicenter study.
Ferraro D, Simone AM, Adani G, Vitetta F, Mauri C, Strumia S, Senesi C, Curti E, Baldi E, Santangelo M, Montepietra S, Immovilli P, Guareschi A, Neri W, Granella F, Caniatti L, Tola MR, Motti L, Pesci I, Montanari E, Sola P. Ferraro D, et al. Among authors: vitetta f. Neurol Sci. 2017 Aug;38(8):1453-1459. doi: 10.1007/s10072-017-2999-1. Epub 2017 May 24. Neurol Sci. 2017. PMID: 28536948 Free article.
Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.
Ferraro D, De Biasi S, Vitetta F, Simone AM, Federzoni L, Borghi V, Cossarizza A, Nichelli PF, Sola P. Ferraro D, et al. Among authors: vitetta f. J Neuroimmune Pharmacol. 2013 Dec;8(5):1059-61. doi: 10.1007/s11481-013-9510-4. Epub 2013 Oct 27. J Neuroimmune Pharmacol. 2013. PMID: 24163092 No abstract available.
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D. Baldi E, et al. Among authors: vitetta f. Curr Med Res Opin. 2014 Sep;30(9):1849-55. doi: 10.1185/03007995.2014.921144. Epub 2014 May 28. Curr Med Res Opin. 2014. PMID: 24831186 Free article.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Simone AM, Ferraro D, Vitetta F, Marasca R, Bonacorsi G, Pinelli G, Federzoni L, Nichelli PF, Sola P. Simone AM, et al. Among authors: vitetta f. Neurology. 2014 Jul 22;83(4):374-5. doi: 10.1212/WNL.0000000000000614. Epub 2014 Jun 18. Neurology. 2014. PMID: 24944259 No abstract available.
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: vitetta f. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.
Trentini A, Manfrinato MC, Castellazzi M, Tamborino C, Roversi G, Volta CA, Baldi E, Tola MR, Granieri E, Dallocchio F, Bellini T, Fainardi E; Emilia-Romagna network for Multiple Sclerosis (ERMES) study group. Trentini A, et al. Mult Scler. 2015 Aug;21(9):1121-30. doi: 10.1177/1352458514560925. Epub 2015 Feb 6. Mult Scler. 2015. PMID: 25662349
61 results